drugset
drugset / Trial / NCT00881231

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

NCT00881231 ↗

Phase 1 Completed 26 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Timeline

Start
2004-01
Primary completion
2004-02
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 50 mg —

Indications

No indication recorded.